- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05193201
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
December 31, 2021 updated by: Shenyang Sunshine Pharmaceutical Co., LTD.
A Multicenter Phase Ib Clinical Study for Recombinant Human Thrombopoietin Injection in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
The purpose of this study is to explore the multiple-dose regimen of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, open label, phase Ib clinical study.
The effectiveness of the multiple-dose regimen of recombinant human thrombopoietin injection in the treatment of thrombocytopenia in patients with chronic liver disease is mainly verified by evaluating the proportion of responders with platelet count in the first 8 days after treatment.
Cohort 1 (n=18) : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L.
Cohort 2 (n=36) : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.
Study Type
Interventional
Enrollment (Anticipated)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
Contact:
- Yimin Cui, PhD
- Phone Number: 010-66110802
- Email: cuiymzy@126.com
-
Contact:
- Xiaoyuan Lin, Master
- Phone Number: 010-83575787
- Email: xiaoyuanxu6@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Gender: There is no limit to men and women.
- 18 years old to 75 years old.
- Liver cirrhosis diagnosed by biopsy/imaging due to chronic liver disease, and Child-Pugh classification is A and B. Patients with liver cirrhosis diagnosed by transient elastography technology can also be included in the group.
- Baseline platelet level: 30×10^9/L≤platelet count<75×10^9/L.
- Liver function ALT and aspartate aminotransferase (AST)≤5×ULN, total bilirubin≤1.5×ULN, blood creatinine≤1.5×ULN.
- Able to understand and be willing to comply with the requirements of the clinical trial protocol, and voluntarily sign a written informed consent form.
Exclusion Criteria:
- Those who are known to be allergic to any component of this product.
- Patients with liver cirrhosis caused by drug-induced liver damage.
- Those with a history of splenectomy or liver transplantation.
- Previously or currently suffering from serious diseases of any organ or system other than the liver, including cardiovascular disease, blood system disease, and nervous system disease patients, as well as any other diseases judged by the investigator to be unsuitable for participating in this trial.
- Currently suffering from malignant tumors, including solid tumors and hematological malignancies.
- Those who are clearly diagnosed as liver failure.
- Liver cirrhosis with serious complications, including: hepatic encephalopathy, refractory ascites, upper gastrointestinal bleeding, etc.;.
- People who have previously or are currently suffering from any disease that may lead to reduced platelet count and/or abnormal platelet function except for chronic liver disease and cirrhosis, including aplastic anemia, myelodysplastic syndrome, myelofibrosis, etc.
- Those who have undergone intrahepatic portosystemic shunt via jugular vein in the past.
- Doppler ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI) and other imaging examinations that indicate the presence of portal vein thrombosis within 28 days before administration.
- Use heparin, warfarin, non-steroidal anti-inflammatory drugs, aspirin, verapamil, and ticlopidine or glycoprotein IIb/IIIa antagonist (such as tirofiban) within 7 days before administration treat.
- Interferon has been used within 14 days before administration.
- Have received platelet transfusion or used platelet-containing blood products within 14 days before administration, except for transfusion of concentrated red blood cells.
- Those who have received any platelet-increasing therapy within 28 days before administration (the platelet-increasing function of Li Kejun, caffeic acid tablets and/or certain Chinese medicines or Chinese patent medicines that have the function of increasing platelet function can be accepted within 14 days), including but not Limited to rhTPO.
- No more than 28 days after the cessation of other research drug treatments or device research treatments carried out before the administration.
- There are currently patients with WHO ≥ Grade 2 active bleeding, or those with active bleeding in the past 2 weeks.
- Known human immunodeficiency virus positive or Treponema pallidum antibody positive.
- Combined with severe infections that cannot be effectively controlled (except for chronic hepatitis B and chronic hepatitis C).
- The subjects did not agree to take effective contraceptive measures during the trial period. The female subjects had a positive blood pregnancy test during the screening period; women who were pregnant or breastfeeding or had pregnancy plans within 3 months.
- Subjects' understanding, communication and cooperation are not enough to guarantee that the research will be carried out in accordance with the protocol.
- The researcher believes that the subjects are not suitable to participate in this study due to other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L
The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
|
recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Other Names:
|
Experimental: Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.
The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
|
recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of responders with platelet count
Time Frame: Up to 8 days
|
Based on the results of routine blood tests, calculate the proportion of responders with platelet counts in the first 8 days after treatment
|
Up to 8 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of responders with platelet count
Time Frame: Up to 36 days
|
Based on the results of routine blood tests, calculate the proportion of responders with platelet counts during the study
|
Up to 36 days
|
Platelet count
Time Frame: Up to 36 days
|
Based on the results of routine blood tests, calculate the change in platelet count from baseline at different visit times after treatment.
Calculate the duration of alleviation of thrombocytopenia symptom relief to different levels (≥50×10^9/L; ≥75×10^9/L; ≥100×10^9/L).
|
Up to 36 days
|
Platelet peak
Time Frame: Up to 36 days
|
Based on the results of routine blood tests, observe the peak value of platelets and record the peak time after treatment.
|
Up to 36 days
|
AE
Time Frame: Up to 36 days
|
All adverse events related to rhTPO observed through various tests (including blood routine, liver function, pregnancy test, electrocardiogram, etc.)
|
Up to 36 days
|
Immunogenicity of rhTPO
Time Frame: At Day 1, Day 14, Day 36
|
Detect the presence of anti-rhTPO antibodies through the subject's blood sample
|
At Day 1, Day 14, Day 36
|
Cmax
Time Frame: Up to 36 days
|
Detect the blood concentration of rhTPO by the subject's blood sample
|
Up to 36 days
|
AUC
Time Frame: Up to 36 days
|
Detect the blood concentration of rhTPO by the subject's blood sample, then calculate the area under the curve (AUC)
|
Up to 36 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yimin Cui, PhD, Peking University First Hospital
- Principal Investigator: Xiaoyuan Lin, Master, Peking University First Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 16, 2022
Primary Completion (Anticipated)
October 16, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
December 31, 2021
First Submitted That Met QC Criteria
December 31, 2021
First Posted (Actual)
January 14, 2022
Study Record Updates
Last Update Posted (Actual)
January 14, 2022
Last Update Submitted That Met QC Criteria
December 31, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3SBio-TPO-106-Ib-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopenia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Assistance Publique Hopitaux De MarseilleWithdrawnNeonatal Thrombocytopenia Isoimmunization Maternal-fetalFrance
Clinical Trials on recombinant human thrombopoietin injection
-
First Affiliated Hospital Xi'an Jiaotong UniversityShenyang Pharmaceutical UniversityUnknown
-
Shandong UniversityShandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...CompletedImmune ThrombocytopeniaChina
-
Tianjin Medical University General HospitalUnknown
-
Peking Union Medical CollegeShenyang Sunshine Pharmaceutical Co., LTD.UnknownThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic PurpuraChina
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.Unknown
-
Nanfang Hospital of Southern Medical UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsUnknownAllogeneic Hematopoietic Stem Cell Transplantation | Myeloablative | Delayed Platelet EngraftmentChina
-
Institute of Hematology & Blood Diseases HospitalCompleted
-
Chinese Society of Lung CancerTerminatedCarcinoma, Non-Small-Cell LungChina
-
Nanfang Hospital of Southern Medical UniversityThe Third Affiliated Hospital of Southern Medical University; The Second People... and other collaboratorsNot yet recruitingPneumonia | Thrombocytopenia